Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
As of June 30, 2019, Sabraâs investment portfolio included 432 real estate prope...
As of June 30, 2019, Sabraâs investment portf...
BioTelemetry, Inc. is the leading remote medical technology company focused on the...
BioTelemetry, Inc. is the leading remote medica...
Reliv International, based in Chesterfield, MO, produces nutritional supplements t...
Reliv International, based in Chesterfield, MO,...
Utah Medical Products IncÂŽ, established in 1978, develops, manufactures and marke...
Utah Medical Products IncÂŽ, established in 197...
Fonar Corporation, the MRI Specialistâ˘, is the worldâs leading developer and m...
Fonar Corporation, the MRI Specialistâ˘, is th...
Check-Cap is a clinical-stage medical diagnostics company developing C-ScanÂŽ, the...
Check-Cap is a clinical-stage medical diagnosti...
Scopus BioPharma develops small molecule therapeutics leveraging world-class exper...
Scopus BioPharma develops small molecule therap...
Join the National Investor Network and get the latest information with your interests in mind.